Physician

David S Mezebish, M.D.

According to 2025 Medicare claims, David Mezebish, M.D. (NPI: 1720059736) practices dermatology in the Frederick-Gaithersburg-Bethesda, MD market, with the plurality of this provider's patient population coming from Frederick, MD. This provider's primary affiliated billing organization is MARYLAND SKIN CANCER SPECIALISTS, PA (NPI: 1083799688; TIN: 061722206) and primary practice location at 21702-4895.

Mezebish's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 678 traditional Medicare patients, billed 17,535 HCPCS/CPT codes, and received $774,928 in Medicare payments. The top billing code was 17311 (Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks). Part D data shows 329 prescription claims across 190 beneficiaries totaling $4,271 in drug costs, led by Fluorouracil (Fluorouracil). No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $5,391 and ending at $4,271. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	526	3,551	$734,622
2016	602	3,945	$818,978
2017	643	4,200	$861,485
2018	669	4,072	$893,052
2019	653	4,549	$960,705
2020	610	4,115	$870,758
2021	691	6,569	$1,029,689
2022	653	15,835	$960,970
2023	847	13,120	$978,044
2024	678	17,535	$774,928

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	135	234	$5,391
2016	127	231	$5,139
2017	83	156	$5,175
2018	97	159	$2,292
2019	87	156	$5,389
2020	92	187	$1,555
2021	109	184	$1,701
2022	142	258	$2,678
2023	159	250	$3,155
2024	190	329	$4,271

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
17311	Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks	491	700	$478
17312	Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks	219	389	$306
12032	Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm	206	301	$139
12052	Intermediate repair of wound of face, ears, eyelids, nose, lips, or mouth, 2.6-5.0 cm	249	297	$118
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	186	267	$49

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Fluorouracil	Fluorouracil	23	603	$1,493
Cephalexin	Cephalexin	125	781	$1,216
Ciprofloxacin Hcl	Ciprofloxacin Hcl	47	464	$382
Mupirocin	Mupirocin	18	409	$194
Gentamicin Sulfate	Gentamicin Sulfate	11	177	$163

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

Explore More Providers

FAQ

What Medicare data is available for David S. Mezebish, M.D.?

Tedicare shows public-source Medicare data for David S. Mezebish, M.D. (NPI 1720059736), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does David S. Mezebish, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to David S. Mezebish, M.D.?

David S. Mezebish, M.D. is linked to MARYLAND SKIN CANCER SPECIALISTS, PA (billing NPI 1083799688) in the available physician profile data.

Does David S. Mezebish, M.D. have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.